Efficacy of propranolol and pingyangmycin, respectively, combined with pulsed dye laser on children with hemangioma

Huang,Zhiyong; Zhang,Ning; Cai,Hanxin; Luo,Kunhui

doi:10.3892/etm.2019.8314

Efficacy of propranolol and pingyangmycin, respectively, combined with pulsed dye laser on children with hemangioma

Authors:
- Zhiyong Huang
- Ning Zhang
- Hanxin Cai
- Kunhui Luo
View Affiliations

Affiliations: Department of Vascular Surgery, The 3rd Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518000, P.R. China
Published online on: December 11, 2019 https://doi.org/10.3892/etm.2019.8314
Pages: 1197-1202
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clinical efficacy of propranolol and pingyangmycin, respectively, combined with pulsed dye laser in the treatment of children with hemangioma was analyzed, to provide a new therapeutic idea for their clinical treatment. A total of 120 children with hemangioma were selected into the study. Children treated with propranolol combined with pulsed dye laser were in group A, those treated with pingyangmycin combined with pulsed dye laser were in group B, and 60 healthy children were selected as control group (group C). Blood samples of children were taken before and after treatment for miR‑4295 detection. The expression of miR‑4295 was observed after treatment, and the total clinical remission rate and adverse reactions after treatment were compared between the two groups. The tumor volume of the two groups was significantly reduced after treatment, with statistically significant difference (P<0.05); miR‑4295 expression was reduced in the two groups (P<0.05); adverse reactions in propranolol group were less than pingyangmycin group during treatment (P<0.05). Propranolol and pingyangmycin, respectively, combined with pulsed dye laser had ideal efficacy on hemangioma in children. Moreover, miR‑4295 was highly expressed in children with hemangioma, and the expression level reduced after two methods of treatment. However, adverse reactions in propranolol group were less and its safety was higher.

View Figures

View References

1	Castrén E, Salminen P, Vikkula M, Pitkäranta A and Klockars T: Inheritance patterns of infantile hemangioma. Pediatrics. 138:e201616232016. View Article : Google Scholar : PubMed/NCBI
2	de Jong S, Itinteang T, Withers AH, Davis PF and Tan ST: Does hypoxia play a role in infantile hemangioma? Arch Dermatol Res. 308:219–227. 2016. View Article : Google Scholar : PubMed/NCBI
3	Darrow DH, Greene AK, Mancini AJ and Nopper AJ; Section on dermatology, section on otolaryngology-head and neck surgery, section on plastic surgery, : Diagnosis and management of infantile hemangioma: Executive summary. Pediatrics. 136:786–791. 2015. View Article : Google Scholar : PubMed/NCBI
4	Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, Phillips RJ, Caceres H, Lopez Gutierrez JC, Ballona R, et al: A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 372:735–746. 2015. View Article : Google Scholar : PubMed/NCBI
5	Zhang L, Yuan WE and Zheng JW: Pharmacological therapies for infantile hemangiomas: A clinical study in 853 consecutive patients using a standard treatment algorithm. Sci Rep. 6:216702016. View Article : Google Scholar : PubMed/NCBI
6	Chinnadurai S, Sathe NA and Surawicz T: Laser treatment of infantile hemangioma: A systematic review. Lasers Surg Med. 48:221–233. 2016. View Article : Google Scholar : PubMed/NCBI
7	Nan YH, Wang J, Wang Y, Sun PH, Han YP, Fan L, Wang KC, Shen FJ and Wang WH: MiR-4295 promotes cell growth in bladder cancer by targeting BTG1. Am J Transl Res. 8:4892–4901. 2016.PubMed/NCBI
8	Zhao F, Yang X, Xu G, Bi J, Lv R and Huo R: Propranolol suppresses HUVEC viability, migration, VEGF expression, and promotes apoptosis by downregulation of miR-4295. J Cell Biochem. 120:6614–6623. 2019. View Article : Google Scholar : PubMed/NCBI
9	Asilian A, Mokhtari F, Kamali AS, Abtahi-Naeini B, Nilforoushzadeh MA and Mostafaie S: Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double-blind randomized controlled trial. Adv Biomed Res. 4:2572015. View Article : Google Scholar : PubMed/NCBI
10	Hogeling M, Adams S and Wargon O: A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 128:e259–e266. 2011. View Article : Google Scholar : PubMed/NCBI
11	Achauer BM, Chang CJ and Vander Kam VM: Management of hemangioma of infancy: Review of 245 patients. Plast Reconstr Surg. 99:1301–1308. 1997. View Article : Google Scholar : PubMed/NCBI
12	Ji Y, Chen S, Li K, Li L, Xu C and Xiang B: Signaling pathways in the development of infantile hemangioma. J Hematol Oncol. 7:132014. View Article : Google Scholar : PubMed/NCBI
13	Greenberger S: Infantile Hemangioma[M]//Sex and Dermatology. Springer Cham; New York, NY: pp. 215–225. 2018
14	Darrow DH, Greene AK, Mancini AJ and Nopper AJ; Section on dermatology, section on otolaryngology-head and neck surgery, section on plastic surgery, : Diagnosis and management of infantile hemangioma. Pediatrics. 136:e1060–e1104. 2015. View Article : Google Scholar : PubMed/NCBI
15	Chinnadurai S, Fonnesbeck C, Snyder KM, Sathe NA, Morad A, Likis FE and McPheeters ML: Pharmacologic interventions for infantile hemangioma: A meta-analysis. Pediatrics. 137:e201538962016. View Article : Google Scholar : PubMed/NCBI
16	Léaute-Labrèze C, Boccara O, Degrugillier-Chopinet C, Mazereeuw-Hautier J, Prey S, Lebbé G, Gautier S, Ortis V, Lafon M, Montagne A, et al: Safety of oral propranolol for the treatment of infantile hemangioma: A systematic review. Pediatrics. 138:e201603532016. View Article : Google Scholar : PubMed/NCBI
17	Ng M, Knuth C, Weisbrod C and Murthy A: Propranolol therapy for problematic infantile hemangioma. Ann Plast Surg. 76:306–310. 2016. View Article : Google Scholar : PubMed/NCBI
18	Hou J, Wang M, Tang H, Wang Y and Huang H: Pingyangmycin sclerotherapy for infantile hemangiomas in oral and maxillofacial regions: An evaluation of 66 consecutive patients. Int J Oral Maxillofac Surg. 40:1246–1251. 2011. View Article : Google Scholar : PubMed/NCBI
19	Huang Y, Li P, Xia S, Zhuo Y and Wu L: Proapoptotic effect and the mechanism of action of pingyangmycin on cavernous hemangiomas. Exp Ther Med. 7:473–477. 2014. View Article : Google Scholar : PubMed/NCBI
20	Tu JB, Li QY, Jiang F, Hu XY, Ma RZ, Dong Q, Zhang H, Pattar P and Li SX: Pingyangmycin stimulates apoptosis in human hemangioma-derived endothelial cells through activation of the p53 pathway. Mol Med Rep. 10:301–305. 2014. View Article : Google Scholar : PubMed/NCBI
21	Kwon SH, Choi JW, Byun SY, Kim BR, Park KC, Youn SW, Huh CH and Na JI: Effect of early long-pulse pulsed dye laser treatment in infantile hemangiomas. Dermatol Surg. 40:405–411. 2014. View Article : Google Scholar : PubMed/NCBI
22	Kessels JP, Hamers ET and Ostertag JU: Superficial hemangioma: Pulsed dye laser versus wait-and-see. Dermatol Surg. 39:414–421. 2013. View Article : Google Scholar : PubMed/NCBI
23	Bertoni N, Pereira LM, Severino FE, Moura R, Yoshida WB and Reis PP: Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangioma. BMC Med Genet. 17:42016. View Article : Google Scholar : PubMed/NCBI